These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 11363102)

  • 1. Four new concepts for combatting HIV infection...and why they won't be tried anytime soon.
    PI Perspect; 1995 Dec; (no 17):1-3, 13-4. PubMed ID: 11363102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral-load testing may lower high cost of therapy.
    AIDS Alert; 1996 Sep; 11(9):100-1. PubMed ID: 11363721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measuring viral load in the clinical setting.
    Harrigan R
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S34-40. PubMed ID: 8595506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Top AIDS researchers' strategy for antiretroviral treatment.
    AIDS Alert; 1996 Sep; 11(9):97-100. PubMed ID: 11363728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protease inhibitors: implications for HIV research and treatment.
    Churchill SA
    J Int Assoc Physicians AIDS Care; 1996 Jan; 2(1):13-8. PubMed ID: 11363325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with virological response in HIV-infected patients failing antiretroviral therapy: a prospective cohort study.
    Fournier S; Chaffaut C; Maillard A; Loze B; Lascoux C; Gérard L; Timsit J; David F; Bergmann JF; Oksenhendler E; Sereni D; Chevret S; Molina JM
    HIV Med; 2005 Mar; 6(2):129-34. PubMed ID: 15807719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zidovudine and lamivudine: results of phase III studies.
    Staszewski S
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S57. PubMed ID: 8595510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protease inhibitors and nucleosides: how many? when? An interview with Stefano Vella, MD. Interview by Mark Mascolini.
    Vella S
    J Int Assoc Physicians AIDS Care; 1995 Dec; 1(11):12-8. PubMed ID: 11363089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Winnipeg conference. What do the numbers mean?
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1995 Jul; 1(6):10-8. PubMed ID: 11362723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
    Pierson T; McArthur J; Siliciano RF
    Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.
    Eron JJ; Benoit SL; Jemsek J; MacArthur RD; Santana J; Quinn JB; Kuritzkes DR; Fallon MA; Rubin M
    N Engl J Med; 1995 Dec; 333(25):1662-9. PubMed ID: 7477218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral drug resistance.
    Japour AJ
    AIDS Clin Care; 1995 Aug; 7(8):63-5, 67. PubMed ID: 11362787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chronic hepatitis C in patients with HIV/HCV coinfection with high CD4+ lymphocytes count].
    Inglot M; Szymczak A; Gładysz A; Małyszczak K; Zalewska M
    Przegl Epidemiol; 2007; 61(3):535-43. PubMed ID: 18069391
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trial design in the era of highly effective antiviral drug combinations for HIV infection.
    DeGruttola V; Hughes M; Gilbert P; Phillips A
    AIDS; 1998; 12 Suppl A():S149-56. PubMed ID: 9632997
    [No Abstract]   [Full Text] [Related]  

  • 16. Closing the circle on HIV--or not.
    Mascolini M
    J Int Assoc Physicians AIDS Care; 1995 Oct; 1(9):10-4, 17-29 contd. PubMed ID: 11362964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of surrogate markers in evaluation of antiviral therapy for HIV infection.
    Deyton L
    JAMA; 1996 Jul; 276(2):159-60. PubMed ID: 8656509
    [No Abstract]   [Full Text] [Related]  

  • 18. Dynamics of the pool of infected resting CD4 HLA-DR- T lymphocytes in patients who started a triple class five-drug antiretroviral regimen during primary HIV-1 infection.
    Sankatsing SU; van Praag RM; van Rij RP; Rientsma R; Jurriaans S; Lange JM; Prins JM; Schuitemaker H
    Antivir Ther; 2003 Apr; 8(2):137-42. PubMed ID: 12741626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV viral load quantification, HIV resistance, and antiretroviral therapy.
    Katzenstein DA; Holodniy M
    AIDS Clin Rev; 1995-1996; ():277-303. PubMed ID: 7488557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use and access to viral load measure assays: the need for validation.
    Agosto M
    Update Natl Minor AIDS Counc; 1995; ():7-8. PubMed ID: 11362791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.